Seeking Alpha

SA Pro author Stephen Simpson's bullish take on Sanofi (SNY) touches on the blockbuster...

SA Pro author Stephen Simpson's bullish take on Sanofi (SNY) touches on the blockbuster potential of the company's MS drug, Lemtrada. A commenter points out Contingent Value Rights on Lemtrada allow investors a pure-play bet on the drug's success. The possible undervaluation of the CVR is covered in an interesting article by SA Pro author Chris DeMuth (along with great comment thread).
Comments (1)
  • SNY has been active at repurchasing GCVRZ as they head into the FDA decision. It will be intesting to see if and when they will be able to buy back more before that milestone.
    17 Feb 2013, 10:29 PM Reply Like
DJIA (DIA) S&P 500 (SPY)